News for ORPH Stock

Pomerantz LLP Announces Notice of Pendency and Proposed Settlement For All Persons Who Purchased, or Otherwise Acquired, The American Depositary Shares of Orphazyme A/S in its September 2020 Initial Public Offering or Between September 29, 2020 and November 4, 2021, Both Dates Inclusive CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C CytRx Comments on Quarterly Results and Recent Strategic Initiatives CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C CytRx Notes Orphazyme’s Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C